Stock vs Stock Comparison

CareDx, Inc. vs Abbott Laboratories

CDNA and ABT are evenly matched across key metrics.

CDNA$39.73
ABT$100.68

🏆 Tale of the Tape

44
CDNAABT
-5.6%Profitability (Net Margin)14.7%
Valuation (P/E)27.7x
-6.1%Efficiency (ROIC)10.1%
5/9Health (Piotroski F)5/9
3.2Safety (Altman Z)4.9
13.8%Growth (Rev YoY)5.7%
0.13Risk (Sharpe 1Y)-0.98
0.36xBalance Sheet (D/E)0.64x
4.55%FCF Yield4.18%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.313
252-Day Correlation
0.271
126-Day Correlation

Moderately correlated — some diversification benefit from holding both.

Fundamentals

MetricCDNAABT
Market Cap$2.1B$175.4B
P/E Ratio27.7x
Forward P/E35.0x16.6x
P/B6.50x3.35x
Dividend Yield0.03%
Beta2.430.61

Quantitative Metrics

MetricCDNAABT
DCF Fair Value$6.84$67.82
DCF Upside-59.4%-32.6%
Piotroski F5/95/9
Altman Z3.214.89
Beneish M-3.32-2.53
FCF Yield4.55%4.18%
Net Debt/EBITDA0.1x
ROIC-6.1%10.1%
WACC19.9%8.4%
ROIC – WACC-26.0pp1.7pp
Gross Margin67.5%56.4%
Net Margin-5.6%14.7%
Rev Growth YoY13.8%5.7%
Sharpe (1Y)0.13-0.98
Max Drawdown 3Y-66.0%
FCF Payout Ratio56%

CDNA Price

Loading chart...

ABT Price

Loading chart...

ETF Exposure

CDNA found in:

ARKG4.19%
XBI0.46%
VHT0.02%

ABT found in:

IHI16.93%
XLV2.94%
IYH2.64%
VHT2.33%
XHE1.71%
DGRW1.43%
NOBL1.34%
SDY1.07%
MGV0.75%
VIG0.69%
VFMV0.69%
SCHV0.68%
VYM0.65%
VTV0.59%
IWD0.58%
SPYV0.58%
VONV0.44%
IVV0.41%
QUS0.37%
SPLG0.37%
ESGV0.36%
ITOT0.36%
SCHX0.33%
SCHB0.30%
SPY0.27%
SPTM0.25%
VOO0.24%
URTH0.24%
VONE0.23%
VTI0.22%
ACWI0.16%
RSP0.16%
VT0.13%
ONEO0.05%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

CDNA vs ABT: Head-to-Head Analysis

CareDx, Inc. (CDNA) and Abbott Laboratories (ABT) represent two companies in the Healthcare sector. Our quantitative Tale of the Tape shows these companies are evenly matched across profitability, valuation, and risk metrics.

In terms of capital efficiency, CDNA generates a return on invested capital (ROIC) of -6.1% compared to ABT's 10.1%. This suggests ABT is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between CDNA and ABT is 0.313, indicating moderate co-movement, with some diversification value from holding both in a portfolio context.

CDNA appears in 3 ETFs tracked by SecuritiesDB, while ABT appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, CDNA or ABT?

Our quantitative analysis compares CDNA and ABT across nine fundamental dimensions. CDNA and ABT are evenly matched across key metrics. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are CDNA and ABT correlated?

The 252-day correlation between CDNA and ABT is 0.313. They show moderate correlation — partially diversifying.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.